Topical or Oral Minoxidil for Hair Loss from Breast Cancer Treatment

Overseen By The Ohio State University Comprehensive Cancer Center

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Recruiting

Sponsor: Ohio State University Comprehensive Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial studies the effects of minoxidil, either as a foam applied to the scalp or taken as a pill, in breast cancer patients who lose hair due to their treatment. The goal is to see if minoxidil can help regrow hair and improve their quality of life. Minoxidil has been shown to be effective for different types of hair loss and has been used in various forms to treat this condition.

Research Team

Brittany L Dulmage, MD

Principal Investigator

Ohio State University Comprehensive Cancer Center

Eligibility Criteria

This trial is for women aged 18 or older with stage I-IV breast cancer who are experiencing hair loss since starting endocrine therapy, including tamoxifen or aromatase inhibitors. It's not suitable for pregnant/nursing women, those on recent chemotherapy, with certain types of alopecia, untreated thyroid/iron issues, prior minoxidil use, or a known sensitivity to it.

Inclusion Criteria

I have been diagnosed with breast cancer at any stage.

I have experienced hair loss since starting hormone therapy.

I am currently on hormone therapy for my cancer.

Exclusion Criteria

You are allergic to minoxidil.

Pregnant or nursing women

I have used chemotherapy in the past 2 years or am currently using it.

Treatment Details

Interventions

• Minoxidil (Vasodilator)

Trial Overview The study is testing whether topical or oral Minoxidil can help treat hair loss caused by endocrine therapy in breast cancer patients. The trial includes questionnaires and quality-of-life assessments to evaluate the effectiveness and side effects of the treatment.

Participant Groups

Group I: Arm II (orally minoxidil) Experimental Treatment 3 Interventions

Patients receive minoxidil PO QD for up to 12 months in the absence of disease progression or unacceptable toxicity.

Group II: Arm I (topical minoxidil) Active Control 3 Interventions

Patients apply minoxidil foam topically to affected areas of the scalp QD for up to 12 months in the absence of disease progression or unacceptable toxicity.

Who Is Running the Clinical Trial?

Ohio State University Comprehensive Cancer Center

Lead Sponsor

Trials

350

Recruited

295,000+